Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Disseminated tuberculosis secondary to adalimumab.

Pednekar M, Chandra AB, Chandra PA.

Am J Ther. 2012 Jul;19(4):e139-40. doi: 10.1097/MJT.0b013e3181ee7391.

PMID:
20838203
2.

Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.

Nisar MK, Rafiq A, Östör AJ.

Clin Rheumatol. 2015 Dec;34(12):2141-5. doi: 10.1007/s10067-015-3099-3. Epub 2015 Oct 24.

PMID:
26497501
3.

Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.

Malaviya AN, Kapoor S, Garg S, Rawat R, Shankar S, Nagpal S, Khanna D, Furst DE.

J Rheumatol. 2009 Jul;36(7):1414-20. doi: 10.3899/jrheum.081042. Epub 2009 Jun 1.

PMID:
19487263
4.

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, Carreño L, Figueroa M; BIOBADASER Group.

Arthritis Rheum. 2005 Jun;52(6):1766-72.

5.

Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N.

Rheumatol Int. 2012 Sep;32(9):2675-9. doi: 10.1007/s00296-011-2030-8. Epub 2011 Jul 26.

PMID:
21789614
6.
7.

Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.

Chang B, Park HY, Jeon K, Ahn JK, Cha HS, Koh EM, Kang ES, Koh WJ.

Clin Rheumatol. 2011 Dec;30(12):1535-41. doi: 10.1007/s10067-011-1771-9. Epub 2011 May 10.

PMID:
21556777
8.

Oral tuberculosis in a patient with rheumatoid arthritis after long treatment with methotrexate and adalimumab.

Barouta G, Karapetsa M, Kostopoulou E, Alexiou I, Koukoulis G, Sakkas LI.

J Clin Rheumatol. 2010 Oct;16(7):330-1. doi: 10.1097/RHU.0b013e3181f3c003.

PMID:
20859224
9.

Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.

Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D.

Int J Tuberc Lung Dis. 2006 Oct;10(10):1127-32.

PMID:
17044206
10.

[The clinical application of quantiferon TB-2G: its usefulness and limitations].

Sato S, Nagai H.

Kekkaku. 2011 Feb;86(2):101-12. Japanese.

PMID:
21404654
11.

Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis.

Murakami S, Takeno M, Kirino Y, Kobayashi M, Watanabe R, Kudo M, Ihata A, Ueda A, Ohno S, Watanuki Y, Kaneko T, Ishigatsubo Y.

Tuberculosis (Edinb). 2009 Mar;89(2):136-41. doi: 10.1016/j.tube.2008.12.004. Epub 2009 Feb 10.

PMID:
19211305
12.

[Two cases of tuberculosis after treatment of rheumatoid arthritis with infliximab].

Takasaka N, Toyota E, Shimada M, Ariga H, Teramoto S, Akagawa S.

Nihon Kokyuki Gakkai Zasshi. 2010 Jan;48(1):60-5. Japanese.

PMID:
20163024
13.

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.

Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, National Psoriasis Foundation.

J Am Acad Dermatol. 2008 Aug;59(2):209-17. doi: 10.1016/j.jaad.2008.03.023. Epub 2008 May 15.

PMID:
18485527
14.

Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment.

Denis B, Lefort A, Flipo RM, Tubach F, Lemann M, Ravaud P, Salmon D, Mariette X, Lortholary O; RATIO Group.

Clin Microbiol Infect. 2008 Feb;14(2):183-6. Epub 2007 Dec 10.

15.

Miliary tuberculosis following negative latent tuberculosis infection screening prior to tumor necrosis factor-α antagonists: implications for management?

Teh BW, Street AC, McBryde ES, Denholm JT.

J Rheumatol. 2012 Jun;39(6):1297-8. doi: 10.3899/jrheum.111577. No abstract available.

PMID:
22661422
16.

Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.

Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL.

Ann Rheum Dis. 2012 Feb;71(2):231-7. doi: 10.1136/annrheumdis-2011-200489. Epub 2011 Oct 21.

PMID:
22021896
17.

Tuberculous pleurisy diagnosed by medical thoracoscopy in an adalimumab-treated rheumatoid arthritis patient after treatment of latent tuberculosis infection.

Nagafuchi Y, Shoda H, Fujio K, Ishii S, Sugiyama H, Yamamoto K.

Mod Rheumatol. 2013 Sep;23(5):1013-7. doi: 10.1007/s10165-012-0727-5. Epub 2012 Aug 1.

PMID:
22911136
18.

The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature.

Scrivo R, Sauzullo I, Mengoni F, Riccieri V, Altieri AM, Cantoro L, Vullo V, Mastroianni CM, Valesini G.

Clin Rheumatol. 2016 May;35(5):1383-8. doi: 10.1007/s10067-014-2669-0. Epub 2014 May 15. Review.

PMID:
24827875
19.

How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.

Bermejo F, Algaba A, Chaparro M, Taxonera C, Garrido E, García-Arata I, Guerra I, Gisbert JP, Olivares D, de-la-Poza G, López-Sanromán A.

Dig Liver Dis. 2013 Sep;45(9):733-7. doi: 10.1016/j.dld.2013.03.005. Epub 2013 Apr 12.

PMID:
23587496
20.

Central nervous system manifestations of tuberculosis-associated immune reconstitution inflammatory syndrome during adalimumab therapy: a case report and review of the literature.

Tanaka T, Sekine A, Tsunoda Y, Takoi H, Lin SY, Yatagai Y, Hayasihara K, Saito T.

Intern Med. 2015;54(7):847-51. doi: 10.2169/internalmedicine.54.2828. Epub 2015 Apr 1. Review.

Supplemental Content

Support Center